Status:
COMPLETED
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
Lead Sponsor:
Takeda
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
35-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or...
Detailed Description
Diabetes mellitus is one of the most common non-communicable diseases worldwide. More than 22 million persons have been diagnosed with diabetes in the European region of the International Diabetes Fed...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Type 2 diabetes mellitus
- Glycosylated hemoglobin above the upper limit of normal (ie, the local equivalent of 6.5% for)
- Established history of macrovascular disease, defined as 1 or more of:
- Myocardial infarction at least 6 months before entry into the study.
- Stroke at least 6 months before entry into the study
- Percutaneous coronary intervention or coronary artery bypass graft at least 6 months before entry into the study.
- Acute coronary syndrome at least 3 months before entry into the study.
- Objective evidence of coronary artery disease.
- Peripheral arterial obstructive disease
- Exclusion Criteria
- Signs of type 1 diabetes.
- Patients prescribed insulin as sole therapy for glycemic control of diabetes for 2 weeks or more at any time in the previous 3 months.
- Myocardial infarction, stroke, coronary artery bypass graft, or percutaneous cardiac intervention in the 6 months prior to enrolment.
- Acute coronary syndrome in the 3 months prior to enrolment.
- Heart failure at entry defined as patient having a New York Heart Association functional score of II or above.
- Had an appointment for a coronary angiogram or endovascular or surgical intervention.
- Leg ulcers, gangrene, or ischemic rest pain.
- Had an appointment for an angiogram or endovascular or surgical intervention for leg ischemia.
- Had undergone a major operation (defined as a surgical procedure lasting for more than 30 minutes) at any time in the previous 4 weeks.
- Significantly impaired hepatic function, defined as alanine aminotransferase greater than 2.5 times the upper limit of normal.
- Familial polyposis coli.
- Required dialysis.
- History of alcohol or drug abuse.
- Any other intercurrent disease believed to be likely to have a significant impact on the patient's life expectancy during the course of the study (eg, cancer).
- Patient was undergoing follow-up as part of another clinical trial or less than 3 months had elapsed since the last dose of an investigational drug or procedure.
- Hypersensitivity to pioglitazone or other TZD.
- Current use of pioglitazone or other TZD.
- Patient was known to be infected with human immunodeficiency virus or was known to have viral hepatitis.
- Women who were any of the following: pregnant, breast feeding, wished to become pregnant during the course of the study or of childbearing potential and not planning to use a reliable method of contraception throughout the study.
Exclusion
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
4373 Patients enrolled
Trial Details
Trial ID
NCT00174993
Start Date
May 1 2001
End Date
January 1 2005
Last Update
February 28 2012
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Cities, Austria
2
Multiple Cities, Belgium
3
Multiple Cities, Czechia
4
Multiple Cities, Denmark